• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by BioCardia Inc.

    2/12/25 8:00:15 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCDA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    BioCardia, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    09060U606

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    09060U606


    1Names of Reporting Persons

    Thomas A. Satterfield, Jr.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    87,498.00
    6Shared Voting Power

    300,649.00
    7Sole Dispositive Power

    87,498.00
    8Shared Dispositive Power

    300,649.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    388,147.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.2 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  * Based on 4,584,285 shares of common stock of the issuer outstanding as of November 5, 2024, as reported by the issuer in its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024. This assumes the exercise of 156,982 warrants beneficially owned by the Reporting Person.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    BioCardia, Inc.
    (b)Address of issuer's principal executive offices:

    320 Soquel Way, Sunnyvale, CA 94085
    Item 2. 
    (a)Name of person filing:

    Thomas A. Satterfield, Jr.
    (b)Address or principal business office or, if none, residence:

    15 Colley Cove Drive Gulf Breeze, Florida 32561
    (c)Citizenship:

    Incorporated by reference from Item 4 of the Cover Page.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    09060U606
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Incorporated by reference from Item 9 of the Cover Page.
    (b)Percent of class:

    Incorporated by reference from Item 11 of the Cover Page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Incorporated by reference from Item 5 of the Cover Page.

     (ii) Shared power to vote or to direct the vote:

    Incorporated by reference from Item 6 of the Cover Page.

     (iii) Sole power to dispose or to direct the disposition of:

    Incorporated by reference from Item 7 of the Cover Page.

     (iv) Shared power to dispose or to direct the disposition of:

    Incorporated by reference from Item 8 of the Cover Page.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    With respect to the beneficial ownership report for Thomas A. Satterfield, Jr., 49,999 shares of common stock and 52,150 shares of common stock issuable upon exercise of warrants are held by Tomsat Investment & Trading Co., Inc, a corporation wholly owned by Mr. Satterfield and of which he serves as President; 96,334 shares of common stock and 69,666 shares of common stock issuable upon exercise of warrants are held by A.G. Family L.P., a partnership managed by a general partner controlled by Mr. Satterfield; and 30,000 shares are held by Caldwell Mill Opportunity Fund, LLC which fund is managed by an entity of which Mr. Satterfield owns a 50% interest and serves as Chief Investment Manager. Additionally, Mr. Satterfield has a limited power of attorney for voting and disposition purposes with respect to the following shares: Rebecca A. Satterfield (2,500 shares). Ms. Satterfield has the right to receive or the power to direct the receipt of the proceeds from the sale of her shares.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Thomas A. Satterfield, Jr.
     
    Signature:/s/ Thomas A. Satterfield, Jr.
    Name/Title:Thomas A. Satterfield, Jr.
    Date:02/12/2025
    Get the next $BCDA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCDA

    DatePrice TargetRatingAnalyst
    12/20/2021$9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BCDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Altman Peter bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 2% to 273,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    2/4/26 5:47:41 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,194 worth of shares (900 units at $1.33), increasing direct ownership by 0.34% to 268,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    1/21/26 5:03:15 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,444 worth of shares (1,100 units at $1.31), increasing direct ownership by 0.41% to 267,966 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    12/17/25 6:32:43 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Altman Peter bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 2% to 273,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    2/4/26 5:47:41 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,194 worth of shares (900 units at $1.33), increasing direct ownership by 0.34% to 268,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    1/21/26 5:03:15 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,444 worth of shares (1,100 units at $1.31), increasing direct ownership by 0.41% to 267,966 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    12/17/25 6:32:43 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT)

    SUNNYVALE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced echocardiography data for the CardiAMP Cell Therapy for the treatment of heart failure has been accepted for Late Breaking Clinical Trial Oral Presentation at the Technology and Heart Failure Therapeutics (THT) Meeting, which takes place March 2-4 in Boston, Massachusetts. On behalf of the CardiAMP HF investigators, the presentation will be made by Dr. Amish Raval, M.D., Professor of Medicine at UW School of Medicine and Public Health and CardiAMP HF Trial National Co-Principal

    2/3/26 8:00:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA

    SUNNYVALE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has completed a third preliminary clinical consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA) on our CardiAMP Cell Therapy intended for treatment of Heart Failure with Reduced Ejection Fraction (HFrEF). The meeting was held in further preparation for formal clinical consultation on acceptability of the existing clinical data for submission of an application for approval. Based on the discussions in the most recent meeting, PMDA said it will allow BioCardia to

    12/16/25 8:00:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno

    SUNNYVALE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the election of Mr. Marvin Slosman to its Board of Directors, effective December 2, 2025. Dr. Richard Krasno, who has served on the Board since 2016, has completed his term and departed the Board effective December 2, 2025. "We are very pleased to welcome Mr. Slosman to our Board," said Peter Altman, Chief Executive Officer of BioCardia. "With deep expertise in the interventional cardiology sector and a strong track record in advancing breakthrough technologies from concept

    12/3/25 8:00:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    SEC Filings

    View All

    BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BioCardia, Inc. (0000925741) (Filer)

    2/3/26 8:00:08 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by BioCardia Inc.

    S-8 - BioCardia, Inc. (0000925741) (Filer)

    12/18/25 5:13:25 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BioCardia, Inc. (0000925741) (Filer)

    12/16/25 8:00:11 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on BioCardia with a new price target

    HC Wainwright & Co. initiated coverage of BioCardia with a rating of Buy and set a new price target of $9.00

    12/20/21 6:05:04 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia downgraded by Dawson James

    Dawson James downgraded BioCardia from Buy to Neutral

    4/16/21 7:22:02 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    Leadership Updates

    Live Leadership Updates

    View All

    BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

    SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the appointment of Farhan Shahab as Vice President of Quality. Mr. Shahab brings over 25 years of experience to BioCardia in similar executive roles. Mr. Shahab joins BioCardia from Welldoc (a digital health company focused on chronic disease management), where he served as Vice President of Quality and Regulatory. Prior to that, he served as Senior Director of Regulatory Affairs and Quality Assurance at Intuity Medical (a blood glucose monitoring device company), and as Dir

    11/24/25 8:15:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    Financials

    Live finance-specific insights

    View All

    BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results

    SUNNYVALE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the third quarter of 2025 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. "This quarter's $6 million financing is actively supporting approvability discussions of CardiAMP

    11/12/25 4:40:15 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025

    SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2025 by conference call on Wednesday, November 12, 2025 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10204565/1005a9b26d8. Please note that registered participants will receive their dial-in number upon registration. F

    11/5/25 7:29:23 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results

    SUNNYVALE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2025 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. Recent Business Highlights CardiAMP® autologous cell therapy in ischemic hear

    8/11/25 9:15:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by BioCardia Inc.

    SC 13G - BioCardia, Inc. (0000925741) (Subject)

    9/6/24 7:45:48 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)

    SC 13D/A - BioCardia, Inc. (0000925741) (Subject)

    4/5/24 4:13:08 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)

    SC 13D/A - BioCardia, Inc. (0000925741) (Subject)

    2/27/24 4:53:40 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care